Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Electrocore Inc (ECOR)

Electrocore Inc (ECOR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
electroCore to Participate in Three Upcoming Virtual Investor Conferences

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that Dan Goldberger, Chief Executive Officer, will participate in three upcoming investor conferences:...

ECOR : 0.8490 (+1.91%)
electroCore, Inc. to Present at Little Grapevine's G1 Microcap Virtual Conference

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that that a prerecorded virtual presentation featuring Dan Goldberger, Chief Executive Officer, will...

ECOR : 0.8490 (+1.91%)
ElectroCore, Inc. (ECOR) Reports Q1 Loss, Tops Revenue Estimates

electroCore, Inc. (ECOR) delivered earnings and revenue surprises of -4.00% and 0.55%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

ECOR : 0.8490 (+1.91%)
electroCore Announces First Quarter Financial Results

Generated first quarter revenue of $734,000

ECOR : 0.8490 (+1.91%)
electroCore to Announce First Quarter Ended March 31, 2020 Financial Results on Thursday, May 14

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the first quarter ended March 31, 2020 after the close of the market...

ECOR : 0.8490 (+1.91%)
electroCore Provides Update on COVID-19 Clinical Initiatives

Randomized controlled investigator-initiated trial (IIT) of non-invasive vagus nerve stimulation (nVNS) therapy currently enrolling COVID-19 patients in Spain

ECOR : 0.8490 (+1.91%)
electroCore Provides Business Update and Select First Quarter 2020 Guidance

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided a business update, and introduced select preliminary unaudited guidance for the first quarter of 2020....

ECOR : 0.8490 (+1.91%)
electroCore, Inc. Announces Extension of NHS England's Innovation and Technology Payment (ITP) Program to Fund Continued Use of gammaCore(TM) in the U.K.

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that England's National Health Service (NHS) has exercised its option to extend the Innovation and Technology...

ECOR : 0.8490 (+1.91%)
Thinking about buying stock in Capricor Therapeutics, Chesapeake Energy Corp, electroCore, General Motors, or MGM Resorts?

InvestorsObserver issues critical PriceWatch Alerts for CAPR, CHK, ECOR, GM, and MGM.

CAPR : 4.56 (-1.94%)
CHK : 11.85 (-7.28%)
ECOR : 0.8490 (+1.91%)
GM : 23.42 (-6.09%)
MGM : 16.00 (-1.84%)
electroCore Submits Emergency Use Authorization Application to Allow the Study and Use of gammaCore nVNS Therapy to Treat Respiratory Symptoms Associated with COVID-19

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the company has submitted an Emergency Use Authorization (EUA) application to the U.S. Food and...

ECOR : 0.8490 (+1.91%)
electroCore Announces 510(k) Clearance of gammaCore(TM) Label Expansion into Migraine Prevention

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the company has received Section 510(k) clearance from the U.S. Food and Drug Administration (FDA)...

ECOR : 0.8490 (+1.91%)
electroCore Announces Common Stock Purchase Agreement for up to $25 Million with Lincoln Park Capital

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has entered into a common stock purchase agreement of up to $25 million with Lincoln Park Capital...

LPBC : 5.7000 (-20.83%)
ECOR : 0.8490 (+1.91%)
electroCore Announces Changes to its Board of Directors

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the appointments of three new independent members to its Board of Directors effective April 2, 2020....

ECOR : 0.8490 (+1.91%)
electroCore Announces Fourth Quarter and Full Year 2019 Financial Results

Continued growth in VA and U.K. Channels

ECOR : 0.8490 (+1.91%)
electroCore, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 23, 2020 / electroCore, Inc. (NASDAQ:ECOR) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 23, 2020 at 4:45 PM...

ECOR : 0.8490 (+1.91%)
electroCore to Announce Fourth Quarter and Year Ended December 31, 2019 Financial Results on Monday, March 23

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the fourth quarter and year ended December 31, 2019 after the close...

ECOR : 0.8490 (+1.91%)
electroCore, Inc. Announces Rebate Agreement with Ascent Health Services for gammaCore Preferred Brand Coverage on all Express Scripts Standard National Formularies

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Ascent Health Services on behalf of Express Scripts, one of the nation's leading pharmacy benefit...

ESRX : 92.33 (-3.62%)
ECOR : 0.8490 (+1.91%)
electroCore Provides Business Update and Select Financial Guidance

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided an update on its commercial operations, clinical development programs, and introduced select preliminary...

ECOR : 0.8490 (+1.91%)
electroCore Announces Board of Directors Transition

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the company's current Chairman of the Board, Carrie S. Cox, will resign from the Board effective...

ECOR : 0.8490 (+1.91%)
CB : 124.34 (-2.75%)
NICE Recommends the Use of gammaCore for the Treatment of Cluster Headache in the NHS

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the UK's National Institute for Health and Care Excellence (NICE) has published its medical technologies...

ECOR : 0.8490 (+1.91%)

Van Meerten Stock Picks

My 5 Favorite Mid Caps
Summary 100% technical buy signals with current momentum.
CRUS +1.37 , SEDG -0.74 , THC -0.92 , TER +0.71 , LITE +1.63
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar